Abstract #3746

MRI based assessment of cerebrovascular pathology in Alzheimer’s disease

Ying Xia¹, Nawaf Yassi^2,3, Pierrick Bourgeat¹, Parnesh Raniga¹, Patricia Desmond⁴, Jurgen Fripp¹, David Ames^5,6, Paul Maruff^3,7, Chris Fowler³, Ralph Martins⁸, Victor Villemagne^9,10, Collin Masters³, Christopher Rowe^9,10, and Olivier Salvado¹

¹The Australian e-Health Research Centre, CSIRO Health and Biosecurity, Brisbane, Australia, ²Departments of Medicine and Neurology, The Royal Melbourne Hospital, Parkville, Australia, ³Florey Institute of Neuroscience and Mental Health Research, Parkville, Australia, ⁴Department of Radiology, The Royal Melbourne Hospital, University of Melbourne, Parkville, Australia, ⁵National Ageing Research Institute, Melbourne, Australia, ⁶Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, Australia, ⁷Cogstate, Melbourne, Australia, ⁸Centre of Excellence for Alzheimer’s Disease Research and Care, Edith Cowan University, Joondalup, Australia, ⁹Department of Medicine, Austin Health, University of Melbourne, Heidelberg, Australia, ¹⁰Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia

Cerebrovascular disease often coexists with Alzheimer’s disease (AD) and its contribution to the development of AD remains unclear. This study assessed cerebrovascular pathology in terms of brain infarction and white matter hyperintensities (WMH) in the AIBL study, and investigated its impact on amyloid deposition. Our data revealed significantly greater WMH burden and higher prevalence of cerebrovascular pathology in AD patients. No correlation was found between amyloid load and WMH in either healthy controls, mild cognitive impairment or AD. Moreover, the presence of cerebrovascular pathology showed no association with amyloid deposition in subjects with or without AD.

This abstract and the presentation materials are available to members only; a login is required.

Join Here